Drug profile · INN
vortioxetine
BRINTELLIX
vortioxetine (BRINTELLIX) is a serotonin 3a (5-ht3a) receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — vortioxetine
- US status
- approved
- Class
- Nervous system (N06)
- Route
- ORAL
- Patents
- 1
- Programs
- 29
- Data quality
- 0.84
Quick answer
vortioxetine (BRINTELLIX) is a serotonin 3a (5-ht3a) receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 3a (5-HT3a) receptor antagonist
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is vortioxetine?
vortioxetine (BRINTELLIX) is a serotonin 3a (5-ht3a) receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for vortioxetine?
BRINTELLIX is a marketed brand name for vortioxetine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of vortioxetine?
vortioxetine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.